Breaking News

Tweet TWEET

Notes Redemption, Upcoming Presentations, and Manufacturing Investments - Research Report on Pfizer, Baxter, Lilly, UnitedHealth

  Notes Redemption, Upcoming Presentations, and Manufacturing Investments -
   Research Report on Pfizer, Baxter, Lilly, UnitedHealth Group, and Align
                                  Technology

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 19, 2013

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Baxter International Inc. (NYSE: BAX), Eli Lilly & Co.
(NYSE: LLY), UnitedHealth Group Inc. (NYSE: UNH), and Align Technology, Inc.
(NASDAQ: ALGN). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Pfizer Inc. Research Report

On November 14, 2013, Pfizer Inc. (Pfizer) announced that Wyeth LLC, the
Company's wholly owned subsidiary, has notified The Bank of New York Mellon,
as trustees under the applicable indenture, of its election to fully redeem
all of its outstanding 5.5% Notes due February 1, 2014 (CUSIP No. 983024AE0)
(the Notes). Pfizer informed that the aggregate principal amount of Notes
currently outstanding is c.$1.8 billion, and the redemption date for the Notes
will be December 16, 2013. Pfizer added that the redemption price for the
notes will be a price equal to the greater of 100% of the principal amount of
the Notes or the sum, as determined by the Quotation Agent (as defined in the
Global Note, the form of which was filed with the Securities and Exchange
Commission as part of Exhibit 4.6 to Wyeth's Annual Report on Form 10-K for
the fiscal year ended December 31, 2003 (File No. 001-01225), of the present
value of the principal amount of the Notes and the remaining scheduled
payments of interest on the Notes from the Redemption Date to the maturity
date of the Notes, exclusive of interest accrued to the Redemption Date,
discounted from their respective scheduled payment dates to the Redemption
Date on a semiannual basis (assuming a 360-day year of twelve 30-day months)
at the Treasury Rate (as defined in the Global Note) plus 25 basis points,
plus accrued and unpaid interest on the principal amount being redeemed to
(but excluding) the Redemption Date. The Full Research Report on Pfizer Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

Baxter International Inc. Research Report

On November 14, 2013, Baxter International Inc. (Baxter) announced that the
Company will present at the 25^th Annual Piper Jaffray Healthcare Conference
on December 3, 2013, at 12:00 p.m. CT. Baxter added that a live webcast of its
presentation will be accessible through its corporate website and will be
available for replay until January 2, 2014. The Full Research Report on Baxter
International Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/163d_BAX

--

Eli Lilly & Co. Research Report

On November 14, 2013, Eli Lilly & Co. (Lilly) announced that the Company will
invest more than $700 million to enhance its global insulin manufacturing
capacity. According to Lilly, the new manufacturing investments will support
both existing and future insulin-based medicines which will be distributed as
follows: $120 million to enhance insulin cartridge manufacturing capacity in
France, $245 million to expand insulin-active-ingredient and delivery device
manufacturing capacity in Indianapolis and Puerto Rico, and $350 million to
expand insulin cartridge manufacturing capacity in China. The Company informed
that its commitment to expand insulin production in China is the latest in a
series of diabetes-related investments in the region, such as the opening of
the Lilly China Research and Development Center at Shanghai in 2012. Lilly
added that it has now raised its manufacturing commitment in 2013 to more than
$1 billion in planned investments in response to the growing diabetes epidemic
and increasing demand for insulin around the world. The Full Research Report
on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/977d_LLY

--

UnitedHealth Group Inc. Research Report

On November 12, 2013, UnitedHealth Group Inc. (UnitedHealth Group) announced
that the Company's NOT ME online platform was named a CES Innovations 2014
Design and Engineering Award honoree. The Company said that the NOT ME online
platform delivers the Diabetes Prevention Program (DPP) via the Internet to
people at their own convenience. Deneen Vojta, Senior Vice President,
UnitedHealth Center for Health Reform and Modernization, said, "Through the
online NOT ME program, consumers learn strategies that can help them lose
weight and improve their health - and they can participate at home or anywhere
they chose that is convenient and fits their busy lifestyles. We are grateful
to be recognized by the CES Innovations Design and Engineering Awards for our
commitment to helping people live healthier lives." The Company's online NOT
ME program will be displayed at the 2014 International CES on January 7, 2014
to January 10, 2014 at The Venetian in Las Vegas. The Full Research Report on
UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73e5_UNH

--

Align Technology, Inc. Research Report

On November 14, 2013, Align Technology, Inc.'s (Align Technology) stock
declined 6.34%, ending the day at $54.68. Over the previous three trading
sessions, shares of Align Technology declined 6.67% compared to the Nasdaq
Composite which gained 1.35% during the same period. The Full Research Report
on Align Technology, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/69b3_ALGN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.